Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Antonia et al. (Fri,) studied this question.

www.synapsesocial.com/papers/699562f810cb51f425ec45ec — DOI: https://doi.org/10.1056/nejmoa1709937

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer· 2006 · 132 citations
2. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody· 2015 · 407 citations
3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study· 2015 · 1,994 citations
4. Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study· 2012 · 71 citations
5. The blockade of immune checkpoints in cancer immunotherapy· 2012 · 13,660 citations